Voyager Therapeutics (VYGR) Income towards Parent Company (2014 - 2026)
Voyager Therapeutics recorded quarterly Income towards Parent Company of -$27.9 million in Q1 2026, down 1.86% quarter-over-quarter from -$27.4 million in Q4 2025, and up 9.94% year-over-year from -$25.4 million in Q1 2025.
Voyager Therapeutics' Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$27.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 9.94% year-over-year to -$27.9 million; the TTM figure through Mar 2026 stood at -$116.6 million (down 37.72% YoY), while the FY2025 annual figure was -$119.7 million, down 84.18% from the prior year.
- Income towards Parent Company came in at -$27.9 million for Q1 2026 at Voyager Therapeutics, down from -$27.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $124.0 million in Q1 2023 to a low of -$34.5 million in Q4 2024.
- A 5-year average of -$7.5 million and a median of -$22.2 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 566.69% in 2022 and jumped 681.85% in 2023, its largest moves.
- Voyager Therapeutics' Income towards Parent Company stood at -$23.6 million in 2022, then jumped by 338.86% to $56.4 million in 2023, then slumped by 161.15% to -$34.5 million in 2024, then advanced by 20.47% to -$27.4 million in 2025, then declined by 1.86% to -$27.9 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$27.9 million, -$27.4 million, and -$27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Voyager Therapeutics | 230.25 Mn | 88.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.94 Mn |
| Dec 31, 2025 | -27.43 Mn |
| Sep 30, 2025 | -27.89 Mn |
| Jun 30, 2025 | -33.38 Mn |
| Mar 31, 2025 | -31.02 Mn |
| Dec 31, 2024 | -34.49 Mn |
| Sep 30, 2024 | -9.04 Mn |
| Jun 30, 2024 | -10.14 Mn |
| Mar 31, 2024 | -11.33 Mn |
| Dec 31, 2023 | 56.40 Mn |
| Sep 30, 2023 | -25.90 Mn |
| Jun 30, 2023 | -22.21 Mn |
| Mar 31, 2023 | 124.04 Mn |
| Dec 31, 2022 | -23.61 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | -19.09 Mn |
| Mar 31, 2022 | -21.32 Mn |
| Dec 31, 2021 | 5.06 Mn |
| Sep 30, 2021 | -25.03 Mn |
| Jun 30, 2021 | -28.54 Mn |
| Mar 31, 2021 | -25.57 Mn |
| Dec 31, 2020 | -23.65 Mn |
| Sep 30, 2020 | 84.78 Mn |
| Jun 30, 2020 | -8.64 Mn |
| Mar 31, 2020 | -23.46 Mn |
| Dec 31, 2019 | -12.57 Mn |
| Sep 30, 2019 | -15.01 Mn |
| Jun 30, 2019 | 11.15 Mn |
| Mar 31, 2019 | -27.17 Mn |
| Dec 31, 2018 | -22.53 Mn |
| Sep 30, 2018 | -20.29 Mn |
| Jun 30, 2018 | -25.54 Mn |
| Mar 31, 2018 | -19.93 Mn |
| Dec 31, 2017 | -11.80 Mn |
| Sep 30, 2017 | -23.35 Mn |
| Jun 30, 2017 | -18.88 Mn |
| Mar 31, 2017 | -16.65 Mn |
| Dec 31, 2016 | -14.67 Mn |
| Sep 30, 2016 | -9.00 Mn |
| Jun 30, 2016 | -9.34 Mn |
| Mar 31, 2016 | -7.19 Mn |
| Dec 31, 2015 | -7.28 Mn |
| Sep 30, 2015 | -3.92 Mn |
| Jun 30, 2015 | -3.82 Mn |
| Mar 31, 2015 | -14.58 Mn |
| Dec 31, 2014 | -4.69 Mn |
| Sep 30, 2014 | -4.01 Mn |